DocMorris Future Growth
Future criteria checks 1/6
DocMorris is forecast to grow earnings and revenue by 52.8% and 15.6% per annum respectively. EPS is expected to grow by 53% per annum. Return on equity is forecast to be -9.7% in 3 years.
Key information
52.8%
Earnings growth rate
53.0%
EPS growth rate
Consumer Retailing earnings growth | 13.6% |
Revenue growth rate | 15.6% |
Future return on equity | -9.7% |
Analyst coverage | Good |
Last updated | 20 Dec 2024 |
Recent future growth updates
Recent updates
It's Down 30% But DocMorris AG (VTX:DOCM) Could Be Riskier Than It Looks
Dec 10DocMorris AG's (VTX:DOCM) Subdued P/S Might Signal An Opportunity
Oct 25Does DocMorris (VTX:DOCM) Have A Healthy Balance Sheet?
Sep 22Would Zur Rose Group (VTX:ROSE) Be Better Off With Less Debt?
Sep 07We Think Zur Rose Group (VTX:ROSE) Has A Fair Chunk Of Debt
Dec 05We Think Zur Rose Group (VTX:ROSE) Has A Fair Chunk Of Debt
Aug 22Is Zur Rose Group (VTX:ROSE) Using Too Much Debt?
Apr 19Earnings Update: Zur Rose Group AG (VTX:ROSE) Just Reported And Analysts Are Trimming Their Forecasts
Mar 22Some Zur Rose Group AG (VTX:ROSE) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 20What Kind Of Investors Own Most Of Zur Rose Group AG (VTX:ROSE)?
Feb 23Is Zur Rose Group's (VTX:ROSE) Share Price Gain Of 210% Well Earned?
Jan 19Zur Rose Group AG (VTX:ROSE) Is Expected To Breakeven In The Near Future
Dec 15Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,507 | -28 | -33 | 22 | 10 |
12/31/2025 | 1,226 | -75 | -67 | -37 | 11 |
12/31/2024 | 1,033 | -92 | -74 | -45 | 12 |
6/30/2024 | 1,003 | -97 | -92 | -63 | N/A |
3/31/2024 | 986 | -107 | -103 | -75 | N/A |
12/31/2023 | 969 | -118 | -115 | -87 | N/A |
9/30/2023 | 934 | -132 | -124 | -90 | N/A |
6/30/2023 | 899 | -146 | -129 | -93 | N/A |
3/31/2023 | 915 | -158 | -136 | -95 | N/A |
12/31/2022 | 931 | -171 | -144 | -97 | N/A |
9/30/2022 | 1,156 | -202 | -178 | -126 | N/A |
6/30/2022 | 1,381 | -232 | -212 | -155 | N/A |
3/31/2022 | 1,554 | -229 | -203 | -143 | N/A |
12/31/2021 | 1,727 | -226 | -194 | -131 | N/A |
9/30/2021 | 1,673 | -193 | -155 | -87 | N/A |
6/30/2021 | 1,619 | -160 | -116 | -43 | N/A |
3/31/2021 | 1,548 | -148 | -122 | -55 | N/A |
12/31/2020 | 1,477 | -136 | -127 | -68 | N/A |
9/30/2020 | 1,431 | -112 | -138 | -88 | N/A |
6/30/2020 | 1,385 | -88 | -149 | -108 | N/A |
3/31/2020 | 1,370 | -70 | -137 | -95 | N/A |
12/31/2019 | 1,356 | -52 | -124 | -83 | N/A |
9/30/2019 | 1,314 | -45 | N/A | N/A | N/A |
6/30/2019 | 1,272 | -39 | -67 | -35 | N/A |
3/31/2019 | 1,240 | -39 | -66 | -34 | N/A |
12/31/2018 | 1,207 | -39 | -65 | -33 | N/A |
9/30/2018 | 1,166 | -37 | N/A | N/A | N/A |
6/30/2018 | 1,125 | -36 | -59 | -30 | N/A |
3/31/2018 | 1,061 | -36 | N/A | N/A | N/A |
12/31/2017 | 990 | -36 | N/A | -22 | N/A |
9/30/2017 | 953 | -34 | N/A | -21 | N/A |
6/30/2017 | 915 | -31 | N/A | -21 | N/A |
3/31/2017 | 900 | -21 | N/A | N/A | N/A |
12/31/2016 | 884 | -13 | N/A | -14 | N/A |
9/30/2016 | 873 | -4 | N/A | N/A | N/A |
6/30/2016 | 861 | 6 | N/A | N/A | N/A |
3/31/2016 | 847 | 4 | N/A | N/A | N/A |
12/31/2015 | 838 | 3 | N/A | 19 | N/A |
9/30/2015 | 857 | 4 | N/A | N/A | N/A |
6/30/2015 | 875 | 5 | N/A | N/A | N/A |
3/31/2015 | 898 | 6 | N/A | N/A | N/A |
12/31/2014 | 920 | 7 | N/A | 7 | N/A |
9/30/2014 | 919 | -3 | N/A | N/A | N/A |
6/30/2014 | 919 | -13 | N/A | N/A | N/A |
3/31/2014 | 917 | -14 | N/A | N/A | N/A |
12/31/2013 | 916 | -15 | N/A | 2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DOCM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DOCM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DOCM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DOCM's revenue (15.6% per year) is forecast to grow faster than the Swiss market (4.2% per year).
High Growth Revenue: DOCM's revenue (15.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DOCM is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/26 19:59 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
DocMorris AG is covered by 21 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Volker Bosse | Baader Helvea Equity Research |
Gerhard Orgonas | Berenberg |
Ashley Wallace | BofA Global Research |